Foundation for Angelman Syndrome Therapeutics
Donations deductibleFoundation for Angelman Syndrome Therapeutics' network
12 peoplei12 people on this map.The large node is the subject of this page. Solid lines are what the register itself records (12). Form 990 filings give names without a person identifier; SEC insider filings carry a CIK.The board
12 listediTime on the board is observed from the annual filings: the IRS files no appointment date, so the bar counts years from the first filing the person appears on - a lower bound, not a filed start date. Names are exactly as filed. The IRS publishes no person identifier, so this edition does not yet link a person across organisations.Tenure and departures are observed across annual filings. Observed tenure is a lower bound - a member may have joined before the first year on record. The organisation reported 12 voting members of its governing body on its latest Form 990 Part VI, which matches the board listed here.| Name | Role as filed | Since | On the board |
|---|---|---|---|
| Ryan Jacob Chair | Chairperson | 2022 | 4 yrs |
| Allyson Berent | Chief Science Officer | 2018 | 8 yrs |
| Amelia Beatty | Company secretary | 2020 | 6 yrs |
| Ben O'Connor | Director | 2018 | 8 yrs |
| Guy Shapiral | Tresurer | 2024 | 2 yrs |
| John Schlueter | Director | 2023 | 3 yrs |
| Karly Warner | Director | 2024 | 2 yrs |
| Kelly David | Director | 2018 | 8 yrs |
| Lauren Hoffer | Director | 2020 | 6 yrs |
| Michael Hanrahan | Vice Chairperson and Tr | 2023 | 3 yrs |
| Nora XU | Director | 2022 | 4 yrs |
| Roy Azout | Director | 2018 | 8 yrs |
Officers and senior leadership
5 listediNamed in Part VII as officers, key employees or highest-compensated staff - not board members, shown for completeness.| Name | Title as filed | On the filings |
|---|---|---|
| Alana Newhouse | President/CEO | since 2022 |
| Kena Pearson | Chief Financial Officer | 2024 |
| Kena Richert | Chief Financial Officer | since 2022 |
| Michele Golombuski | Chief Development Officer | 2024 |
| Ryan K Fischer | Chief Operating Oficer | since 2023 |
Pay and hours
year to 31 December 2024iFrom Part VII of the Form 990: compensation reported for each officer, director, trustee, key employee and highest-paid staff member, and the average hours a week they report. Most board members are unpaid; a blank means nothing was reported. Pay from related organisations is shown separately.| Name | Title as filed | Hours a week | Pay from the organisation | Related organisations | Other |
|---|---|---|---|---|---|
| Ryan K Fischer | Chief Operating Oficer | 40 | $286k | ||
| Alana Newhouse | President/CEO | 40 | $245k | ||
| Kena Pearson | Chief Financial Officer | 40 | $233k | ||
| Michele Golombuski | Chief Development Officer | 40 | $210k | ||
| Ryan Jacob | Chairperson | 18 | $0 | ||
| Michael Hanrahan | Vice Chairperson and Tr | 10 | $0 | ||
| Guy Shapiral | Tresurer | 15 | $0 | ||
| Amelia Beatty | Secretary | 15 | $0 | ||
| Karly Warner | Director | 5 | $0 | ||
| John Schlueter | Director | 15 | $0 | ||
| Kelly David | Director | 10 | $0 | ||
| Ben O'connor | Director | 5 | $0 | ||
| Roy Azout | Director | 5 | $0 | ||
| Lauren Hoffer | Director | 5 | $0 | ||
| Nora Xu | Director | 5 | $0 | ||
| Allyson Berent | Chief Science Officer | 2 | $0 | $510k |
Colorado roster
16 listediOfficers, directors and trustees from the latest filing with the Colorado Secretary of State (document 20263029570). Titles are as filed; some entries are registered agents or custodians of records rather than board members. Source: data.colorado.gov, public domain.| Name | Title as filed |
|---|---|
| Kelly David | Director |
| Ryan Fischer | Chief Operating Officer |
| Meagan Cross | Director |
| John Schlueter | Director, Chair Emeritus |
| Amelia Beatty | Secretary |
| Kena Pearson | Chief Financial Officer |
| Nora Xu | Director |
| Kena Pearson | |
| Jacob Ryan | Chairperson |
| Ryan Jacob | Chairperson |
| Karly Werner | Director |
| Lauren Hoffer | Director |
| Roy Azout | Director |
| Mike Hanrahan | Vice Chairperson |
| Guy Shapira | Treasurer |
| Alana Newhouse | Chief Executive Officer |
About
- Legal name
- Foundation for Angelman Syndrome Therapeutics
- EIN
- 263160079
- Address
- 5900 Balcones Drive 8754, Austin, TX, 78731-4257
- State
- Texas
- Mission
- Angelman syndrome (as) is a neurodevelopmental disorder characterized by global development delays and severe speech impairment. A few individuals with as develop functional speech, but most communicate through a mixture of gestures, eye gaze, adapted sign language and augumentative communication devices. Individuals with as have development delay and intellectual disabilities. Current... (as filed on the Form 990)
- Activity (NTEE)
- H12 Medical research
- IRS classification
- 501(c)03 (tax-exempt under section 501(c)(3) where shown)
- Classified purpose
- Medical Research
- Size band
- 8 (IRS master file code)
- Formed
- 2008
- Principal officer
- Ryan Jacob (as named on the Form 990)
- IRS ruling date
- 1 December 2008
- Status
- Code 01 (unconditional exemption)
- Form 990 filings on record
- 6, latest 2024
- IRS Publication 78
- PC (contributions deductible)
Most connected
Longest observed on the filings
≥8years on the filingsAllyson Berent
≥8years on the filingsBen O'Connor
≥8years on the filingsKelly David
≥8years on the filingsRoy Azout
Latest return
year to 31 December 2024iFigures from the newest Form 990 or 990-EZ in the IRS e-file releases of 2025 and 2026, for the year ending 31 December 2024. US dollars, as filed.- Total assets
- $44.9m
- Total liabilities
- $4.7m
- Net assets or fund balances
- $40.2m
- Contributions and grants received
- $3.7m
- Program service revenue
- $0
- Grants and similar paid out
- $3.7m
- Employees
- 11
- Volunteers
- 291
Filed finances
1 yeariTotals as filed on the IRS Form 990 (revenue and expenses), by tax year.| Tax year | Total revenue | Total expenses | Surplus or deficit |
|---|---|---|---|
| 2024 | $5.4m | $10.4m | Deficit $5m |
As filed on the IRS Form 990. US dollars.
Grants paid
10 listediFrom Schedule I of the Form 990: grants and assistance to organisations in the United States, largest first (up to 25). Schedule I is filed only by organisations that gave more than $5,000 to any one recipient.| Recipient | Purpose | Amount |
|---|---|---|
| University of Pennsylvania | Upenn 2023: research, collaboration & license agreement | $5.9m |
| Boston Children's Hospital | Ft2022-006: abom - natural history study | $471k |
| Rush University Medical Center | $321k | |
| Duke University | Ft2018-005 amended: gpic-comm | $318k |
| Regents of the University of California Davis | Ft2022-007: gastrointestinal biomarkers in preclinical models of angelman syndrome | $274k |
| The Regents of the University of California San Francisco | Ft2023-002: developing a crispra therapy for the classi/ii deletion genotype of angelman syndrome | $211k |
| Brown University | Ft2022-005: development of bdnf potentiating therapeutics for motor and cognitive dysfunction in as | $150k |
| Children's Research Institute | Ft2022-003: peak alpha frequency as an eeg biomarker for angelman syndrome | $141k |
| Keck Graduate Institute of Applied Life Sciences | Ft2022-002: targeting angelman syndrome therapeutics to the brain utilizing novel cell penetrating peptides | $125k |
| Brown University | Pd2023-001: postdoctoral fellowship program | $51k |
State registration
1 entityiBusiness-entity registers published by US states. These records are matched to this organisation by name and state, not by EIN, and are labelled as likely matches. Street addresses are not shown.Foundation for Angelman Syndrome Therapeutics likely matchiMatched by exact name and state (and ZIP where shown). State registers do not publish EINs, so this is not a confirmed match. Source: Colorado Secretary of State (CDOS), business entities (data.colorado.gov 4ykn-tg5h). Licence: public domain. Data last fetched 18 October 2026.
- State
- Colorado
- Entity type
- nonprofit corporation
- Status
- Good Standing
- Formed
- 31 August 2026
- Registered agent
- Cogency Global Inc. (city and state not held)
This register does not publish officers or directors.